Combination of a macrolide T-cell immunomodulator and a calciferol for the treatment of skin diseases or of inflammatory bowel disease

Details for Australian Patent Application No. 2004226820 (hide)

Owner Novartis AG

Inventors Paul, Carle; Hirsch, Stefan; Mayer, Friedrich Karl; Sekkat, Nabila; Grassberger, Maximilian; Meingassner, Josef Gottfried

Agent Davies Collison Cave

Pub. Number AU-B-2004226820

PCT Pub. Number WO2004/087170

Priority 0307865.6 04.04.03 GB

Filing date 2 April 2004

Wipo publication date 14 October 2004

Acceptance publication date 21 February 2008

International Classifications

A61K 31/593 (2006.01)

A61K 31/453 (2006.01)

A61P 1/00 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 17/00 (2006.01) Drugs for dermatological disorders

Event Publications

6 October 2005 PCT application entered the National Phase

  PCT publication WO2004/087170 Priority application(s): WO2004/087170

21 February 2008 Application Accepted

  Published as AU-B-2004226820

19 June 2008 Standard Patent Sealed

27 October 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004226821-Pharmaceutical composition comprising an immunosuppressant for use in the treatment of skin diseases

2004226819-Synergistic combinations of macrolide T-cell modulator or inmunosuppressant and a retinoid